A 32-year-old male from Delhi presents with a 4-month history of productive cough, fever, and night sweats despite receiving standard anti-TB therapy (HRZE) for 3 months. Chest X-ray shows persistent bilateral upper lobe infiltrates with cavitation. Sputum smear microscopy remains positive (2+). Gene Xpert MTB/RIF testing shows *Mycobacterium tuberculosis* detected with RIF resistance. The patient reports poor adherence to treatment in the first month. Which of the following is the most appropriate next step in management?

Explanation

## Clinical Context This patient has **rifampicin-resistant TB (RR-TB)**, confirmed by Gene Xpert MTB/RIF. RIF resistance is the hallmark of MDR-TB (resistance to both INH and RIF). Treatment failure with persistent sputum positivity after 3 months of standard therapy in the setting of RIF resistance mandates immediate switch to MDR-TB regimen. ## MDR-TB Treatment Regimen **Key Point:** MDR-TB requires a longer, more intensive regimen than drug-susceptible TB. The WHO-recommended shorter MDR-TB regimen (20 months total) consists of: - **Intensive phase (6 months):** Fluoroquinolone (levofloxacin/moxifloxacin) + Injectable agent (amikacin/streptomycin) + Pyrazinamide + Ethambutol - **Continuation phase (14 months):** Fluoroquinolone + Pyrazinamide + Ethambutol ## Why Option 1 is Incorrect **Warning:** Continuing HRZE in a RIF-resistant case will lead to treatment failure and progression. RIF resistance = MDR-TB until proven otherwise. ## Why Option 3 is Incorrect Adding ethambutol and streptomycin to HRZE does not address RIF resistance and will not achieve cure in MDR-TB. ## Why Option 4 is Partially Correct but Suboptimal While DST confirmation is ideal, **Gene Xpert MTB/RIF already provides RIF resistance confirmation**. Waiting for additional DST results delays initiation of MDR-TB therapy, which increases mortality and drug resistance amplification. Immediate switch is justified. **High-Yield:** RIF resistance detected on Gene Xpert = presumptive MDR-TB → start MDR regimen immediately, do not wait for INH DST confirmation. **Clinical Pearl:** Poor adherence in month 1 likely selected for RIF-resistant mutants. This is a common scenario in high-burden TB settings. ## Mnemonic: MDR-TB Drugs **FLIPE** = **F**luoroquinolone + **L**evofloxacin (or moxifloxacin) + **I**njectable (amikacin/streptomycin) + **P**yrazinamide + **E**thambutol (continuation phase adds bedaquiline/linezolid if XDR).